{ "ProductData": { "ID": "PID00000006", "ProductType": "Others", "BrandName": "FcRn Affinity Column Gen2", "ProductNameAddition": "prepacked column for affinity chromatography", "RegulatoryDisclaimer1": "For use in quality control/manufacturing process only.", "DisclaimerGroup1": "", "RegulatoryDisclaimer2": null, "DisclaimerGroup2": null, "RegulatoryDisclaimer3": null, "SampleType": [ ], "LicenseDisclaimers": [ ], "RelatedLinks": "", "Clone": "", "ControlTissue": [ "" ], "ISOtypes": "", "Species": [ "" ], "StainLocalization": [ "" ], "ProductNameGlobal": "FcRn Affinity Column Gen2" }, "ProductImageDetails": { "ImagePath": "https://pim-media.roche.com/Images/FcRn_box_and_column.jpg", "ImageType": "Image main" }, "Product2Taxonomy": { "Product2TaxonomyReferences": [ { "StructureSystemIdentifier": "OWP_Product_Types", "StructureSystemName": "Product Types", "NodeID": "20-000-00", "StructureNodeStatus": "valid", "NodeName": "Assays Reagents and Strips" }, { "StructureSystemIdentifier": "OWP_Organization", "StructureSystemName": "Organization", "NodeID": "01-01-01-07-00", "StructureNodeStatus": "valid", "NodeName": "CustomBiotech and LifeScience" }, { "StructureSystemIdentifier": "OWP_Techniques", "StructureSystemName": "Techniques", "NodeID": "290-00", "StructureNodeStatus": "valid", "NodeName": "Affinity Column Chromatography" }, { "StructureSystemIdentifier": "Product_Solutions", "StructureSystemName": "Product Solutions", "NodeID": "520", "StructureNodeStatus": "valid", "NodeName": "CustomBiotech" }, { "StructureSystemIdentifier": "Lab_Type", "StructureSystemName": "Lab Types", "NodeID": "180-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "02-0052", "StructureNodeStatus": "valid", "NodeName": "In vitro Glycoengineering" }, { "StructureSystemIdentifier": "Applications", "StructureSystemName": "Applications", "NodeID": "99-00-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "Disease_Areas", "StructureSystemName": "Disease Areas", "NodeID": "99-00-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "Pathogens", "StructureSystemName": "Pathogens", "NodeID": "99-00-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "OWP_Family", "StructureSystemName": "Product Families", "NodeID": "999", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "Health_Topics", "StructureSystemName": "Health Topics", "NodeID": "99-00-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "02-0008", "StructureNodeStatus": "valid", "NodeName": "Biologics" }, { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "02-0001", "StructureNodeStatus": "valid", "NodeName": "Affinity Columns" } ] }, "Product2Materials": { "P2MaterialReferences": [ { "MaterialNum": "09430857001", "MaterialDescription": "FcRn Affinity Column Gen2", "RegisteredProductName": "FcRn Affinity Column Gen2", "GTIN": "07613336220832", "ProductCategoryText": "Reagents, kits", "OldMaterialNumber": "", "PackSizePIM360": "1 column", "PackSizeDescPIM360": "Not Available", "MaterialAnnotation": "CustomBiotech product. Please contact your local representative.", "ReadyForUse": "", "OrderInformation": "Unit of measure is \"piece\"." } ] }, "Product2Products": { "Product2ProductReference": [ { "ProductID": "PID00000007", "BrandName": "FcRn IgG Control", "ProductNameAddition": "for functional control of the FcRn Affinity Column Gen 2", "ReferenceType": "Control", "Classification": [ { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "90-000-00", "StructureGroupPath": "Controls", "StructureGroupName": "Controls", "StructureNodeStatus": "valid" }, { "IdentifierofStructureSystem": "OWP_Organization", "NameofStructureSystem": "Organization", "StructureNodeID": "01-01-01-07-00", "StructureGroupPath": "Roche Diagnostics Solution (RDS)->Customer Areas->Core lab->CustomBiotech and LifeScience", "StructureGroupName": "CustomBiotech and LifeScience", "StructureNodeStatus": "valid" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "520", "StructureGroupPath": "CustomBiotech", "StructureGroupName": "CustomBiotech", "StructureNodeStatus": "valid" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "180-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "invalid" }, { "IdentifierofStructureSystem": "Product_Grouping", "NameofStructureSystem": "Product Grouping", "StructureNodeID": "02-0052", "StructureGroupPath": "CustomBiotech->In vitro Glycoengineering", "StructureGroupName": "In vitro Glycoengineering", "StructureNodeStatus": "valid" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "invalid" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "invalid" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "invalid" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "999", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "invalid" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "invalid" }, { "IdentifierofStructureSystem": "Product_Grouping", "NameofStructureSystem": "Product Grouping", "StructureNodeID": "02-0008", "StructureGroupPath": "CustomBiotech->Biologics", "StructureGroupName": "Biologics", "StructureNodeStatus": "valid" }, { "IdentifierofStructureSystem": "Product_Grouping", "NameofStructureSystem": "Product Grouping", "StructureNodeID": "02-0001", "StructureGroupPath": "CustomBiotech->Affinity Columns", "StructureGroupName": "Affinity Columns", "StructureNodeStatus": "valid" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "290-00", "StructureGroupPath": "Affinity Column Chromatography", "StructureGroupName": "Affinity Column Chromatography", "StructureNodeStatus": "valid" } ] } ] }, "ProductSpec": [ { "ProductSpecVariant": { "Chapters": [ { "Name": "Positioning", "Value": "The FcRn Affinity Column Gen2 enables fast and convenient analysis of monoclonal IgG antibodies with regard to their structural integrity and for prediction of their half-life in vivo as a therapeutic.", "Language": "en", "Country": "XG", "Code": "Positioning" }, { "Name": "Product Description", "Value": "The prepacked column containing the FcRn matrix is ready for use on common liquid chromatography systems for the chromatographic differentiation of structural variants of IgG.", "Language": "en", "Country": "XG", "Code": "Product Description" }, { "Name": "Applications", "Value": "The FcRn Affinity Column Gen2 is designed for the analysis of monoclonal IgG antibodies for the pharmacokinetical characterization in the development of therapeutics and for the investigation of the structural integrity of IgG preparations in quality control.

The neonatal Fc receptor (FcRn) immobilized in this chromatography column has a specific binding affinity to IgG. The strength and the pH dependency of the binding is different for structural variants of the IgG, and in this way the FcRn chromatography mimics the principle of the in vivo regulation of the antibody clearance from the blood stream. That means, for a specific IgG molecule a later elution in the chromatography with a rising pH predicts a longer half-life in vivo. And even small variations of the IgG structure cause a detectable shift of the elution point in the chromatogram, therefore, different structures can be differentiated, e.g. oxidized or aggregated variants, conjugates, Fc mutations, different Fab fragments.

Furthermore, FcRn has an additional binding site for albumin, and the column can also be used to characterize albumin preparations, e. g. for differentiation of oxidized, aggregated or conjugated variants thereof.", "Language": "en", "Country": "XG", "Code": "Applications" }, { "Name": "Benefits", "Value": "FcRn affinity chromatography provides information about pharmacokinetical characteristics of IgG variants in an easy and standardized way, replacing laborious methods like surface plasmon resonance spectroscopy or manual ELISA testing (reference: T. Schlothauer et. al., mAbs 5:4, 576-586, 2013).", "Language": "en", "Country": "XG", "Code": "Benefits" }, { "Name": "Specification", "Value": "Prepacked chromatography column supplied with standard fittings for liquid chromatography systems (FPLC, HPLC).
Matrix: FcRn protein bound to sepharose matrix
Volume: Approximately 1 ml resin bed volume
Binding capacity: ≥ 100 µg IgG
Reusability: Stable for ≥ 100 injections if used as recommended in the instructions
Maximal system pressure: 5 bar
Maximal flow rate: 0.5 mL/min", "Language": "en", "Country": "XG", "Code": "Specification" }, { "Name": "Content", "Value": "
LabelFunction / DescriptionContent
FcRn Affinity Column Gen2
  • Prepacked chromatography column with 1 mL bed (matrix) volume of FcRn-Biotin-Streptavidin-Sepharose resin.
  • Preassembled with the optimal fittings and filters applicable on all standard liquid chromatography systems, such as FPLC or HPLC.
  • The resin is supplied in storage buffer: 16 mM MES-Na, 4 mM Tris-HCl, 140 mM NaCl, 20 Tablets/L Complete, 0.05% ProClin-300, pH 6.0.
  • Ready-to-use and reusable.
There may be a light white line in the middle of the column. This is not a weakness of the material. The mark is commonly generated in the manufacturing process and does not influence the stability.
1 column
", "Language": "en", "Country": "XG", "Code": "Content" }, { "Name": "CB - Order Information", "Value": "Unit of measure is \"piece\".", "Language": "en", "Country": "XG", "Code": "CB - Order Information" } ] } } ] }

FcRn Affinity Column Gen2

prepacked column for affinity chromatography

fcrn gen2

Enhanced analysis of antibody half-life

The FcRn Affinity Column Gen2 accelerates and standardizes antibody half-life analysis, so you can develop a meaningful lead candidate more quickly.  

The easy-to-use column works on your HPLC and allows you to:

  • monitor antibody behavior at multiple pH values, visualizing even minor differences in antibody and its half-life
  • automate antibody processing
  • eliminate potentially inconsistent coating densities for truly standardized analyses

With FcRn Affinity Column Gen 2 you can characterize and distinguish:
  • IgG variants with different Fab fragments
  • oxidized and native IgG
  • aggregated and monomeric IgG
  • wild-type and engineered IgG
  • antibody isotypes
  • aggregates and unbound serum albumin

  1. Alt, N., et al. (2016) Determination of critical quality attributes for monoclonal antibodies  using quality by design principles, Biologicals 44(5), 291 – 305  
  2. Cymer, F., et al. (2017) Evaluation of an FcRn affinity chromatographic method for IgG1- type antibodies and evaluation of IgG variants, Bioanalysis 9(17), 1305 – 1317 
  3. Datta-Mannan, A., et al. (2014) Application of FcRn binding assays to guide mAb  development, Drug Metab Dispos 42(11), 1867 – 1872
  4. Dostalek, M., et al. (2017) Pharmacokinetic de-risking tools for selection of monoclonal  antibody lead candidates, MAbs 9(5), 756 – 766  
  5. Edelmann, M. R., et al. (2019) Radiolabeled IgG antibodies: Impact of various labels on  neonatal Fc receptor binding, J Labelled Comp Radiopharm 62(11), 751 - 757  
  6. Edelmann, M. R., et al. (2021) Functional in vitro assessment of modified antibodies:  Impact of label on protein properties, PLoS One 16(9), e0257342 
  7. Gahoual, R., et al. (2017) Detailed Characterization of Monoclonal Antibody Receptor  Interaction Using Affinity Liquid Chromatography Hyphenated to Native Mass  Spectrometry, Anal Chem 89(10), 5404 – 5412 
  8. Haberger, M., et al. (2015) Functional assessment of antibody oxidation by native mass  spectrometry, MAbs 7(5), 891 – 900  
  9. Jensen, F. P., et al. (2017) A Two-pronged Binding Mechanism of IgG to the Neonatal  Fc Receptor Controls Complex Stability and IgG Serum Half-life, Mol Cell Proteomics  16(3), 451 – 456  
  10. Jensen, P. F., et al. (2015) Investigating the interaction between the neonatal Fc  receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass  spectrometry, Mol Cell Proteomics 14(1), 148 – 161  
  11. Neuber, T., et al. (2014) Characterization and screening of IgG binding to the neonatal  Fc receptor, MAbs 6(4), 928 – 942  
  12. Piche-Nicolas, N. M., et al. (2018) Changes in complementarity-determining regions  significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics,  MAbs 10(1), 81 – 94  
  13. Pyzik, M., et al. (2019) The Neonatal Fc Receptor (FcRn): A Misnomer?, Front Immunol  10, 1540  
  14. Robbie G. J., et al. (2013) A novel investigational Fc-modified humanized monoclonal  antibody, motavizumab-YTE, has an extended half-life in healthy adults, Antimicrob  Agents Chemother 57(12), 6147 – 6153  
  15. Roopenian, D. C., et al. (2007) FcRn: the neonatal Fc receptor comes of age, Nature  Rev Immunol 7(9), 715 – 725  
  16. Schlothauer, T., et al. (2013) Analytical FcRn affinity chromatography for functional  characterization of monoclonal antibodies, MAbs 5(4), 576 – 586 
  17. Schoch, A., et al. (2015) Charge-mediated influence of the antibody variable domain on  FcRn-dependent pharmacokinetics, Proc Natl Acad Sci USA 112(19), 5997 – 6002  
  18. Sounders, C. A., et al. (2015) A novel in vitro assay to predict neonatal Fc receptor mediated human IgG half-life, MAbs 7(5), 912 – 921  
  19. Stracke, J., et al. (2014) A novel approach to investigate the effect of methionine  oxidation on pharmacokinetic properties of therapeutic antibodies, MAbs 6(5), 1229 –  1242  
  20. Suzuki, T., et al. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the  affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR, J  Immunol 184(4), 1968 – 1976  
  21. Walters, B. T., et al. (2016) Conformational Destabilization of Immunoglobulin G  Increases the Low pH Binding Affinity with the Neonatal Fc Receptor, J Biol Chem  291(4), 1817 – 1825  
  22. Wang, W., et al. (2011) Impact of methionine oxidation in human IgG1 Fc on serum half life of monoclonal antibodies, Mol Immunol 48(6-7), 860 – 866  
  23. Wang, W., et al. (2011) Monoclonal antibodies with identical Fc sequences can bind to  FcRn differentially with pharmacokinetic consequences, Drug Metab Dispos 39(9), 1469  – 1477  
  24. Wang, X., et al. (2017) Impact of SPR biosensor assay configuration on antibody:  Neonatal Fc receptor binding data, MAbs 9(2), 319 – 332  
  25. Wang, Y., et al. (2014) Neonatal Fc receptor (FcRn): a novel target for therapeutic  antibodies and antibody engineering, L Drug Target 22(4), 269 – 278

Ordering Information

Technical documents

for certificates, method sheets (instructions for use), safety data sheets and software downloads
error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later